Ginterferon is a human leukocyte interferon (IFN) produced in the "V. Babes" Institute by in vitro culture of leukocytes separated from neonatal cord blood. Ginterferon (50,000 IU/ml) was administered to 40 patients who suffered for at least two weeks of a hepatic keratoconjunctivitis resistant to treatment with conventional regimens of human immunoglobulins, Iduviran or topical antiinflammatory drugs. In 35 cases (87%) complete recovery (total epithelialization and disappearance of all symptoms) occurred in a significantly shorter time (10-14 days) as compared to similar cases which recovered after 30-40 days by conventional treatment. Local or general untoward effects were not observed in any of the patients. Recovery in the remaining 5 cases was slower, 28-30 days. This slow response may have been due to unusual weakness of the general immunobiological condition in these patients (myocardial infarction or repeated stress) which might have favoured repeated waves of virus spreads from foci of viral latency which are not attained by the topically administered IFN.

Download full-text PDF

Source

Publication Analysis

Top Keywords

ginterferon human
8
human leukocyte
8
leukocyte interferon
8
interferon efficiency
4
efficiency treatment
4
treatment viral
4
viral diseases
4
diseases efficiency
4
efficiency viral
4
viral keratoconjunctivitis
4

Similar Publications

Background: Inflammation is a driver of thrombosis, but the phenomenon of thromboinflammation has been defined only recently, bringing together the multiple pathways involved. models can support the development of new therapeutics targeting the endothelium and also assess the existing immunomodulatory drugs, such as hydroxychloroquine, in modulating the inflammation-driven endothelial prothrombotic phenotype.

Objectives: To develop a model for thrombin generation (TG) on the surface of human endothelial cells (ECs) to assess pro/antithrombotic properties in response to inflammation.

View Article and Find Full Text PDF

Introduction: Our aim was to investigate the insufficiently understood differences in the immune system between anti-citrullinated peptide antibody (ACPA)-positive (ACPA) and ACPA-negative (ACPA) early rheumatoid arthritis (eRA) patients.

Methods: We performed multiple cytokine assays using sera from drug-naïve ACPA and ACPA eRA patients. Additionally, we conducted single-cell RNA sequencing of CD45 cells from peripheral blood samples to analyze and compare the distribution and functional characteristics of the cell subsets based on the ACPA status.

View Article and Find Full Text PDF

Infection with Influenza A virus (IAV) induces severe inflammatory responses and lung injury, contributing significantly to mortality and morbidity rates. Alterations in the microbial composition of the lungs and intestinal tract resulting from infection could influence disease progression and treatment outcomes. Xiyanping (XYP) injection has demonstrated efficacy in clinical treatment across various viral infections.

View Article and Find Full Text PDF

Obstructive sleep apnea (OSA) patients have varying degrees of cognitive impairment, but the specific pathogenic mechanism is still unclear. Meanwhile, poor compliance with continuous positive airway pressure (CPAP) in OSA prompts better solutions. This study aimed to identify differentially expressed genes between the non-obese OSA patients and healthy controls, and to explore potential biomarkers associated with cognitive impairment.

View Article and Find Full Text PDF

Salivary cytokines have the potential to serve as biomarkers for evaluating cancer progression and treatment response in specific cancer types. This study explored salivary cytokine profiles in pediatric cancer patients and healthy controls, examining changes during chemotherapy. We conducted a prospective study involving newly diagnosed cancer patients and healthy controls under 19 years old.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!